Want to see GB:STX full AI Analyst Report?
Shield Therapeutics (STX) Income Statement
Shield Therapeutics Income Statement
Last quarter (Q2 2026), Shield Therapeutics's total revenue was $30.12M, an increase of 148.11% from the same quarter last year. In Q2, Shield Therapeutics's net income was $-2.23M. See Shield Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Dec 24 | Dec 23 | Dec 22 | Jun 22 |
|---|---|---|---|---|---|
| $ 50.74M | $ 32.18M | $ 16.54M | $ 4.48M | $ 1.52M | |
| $ 22.38M | $ 13.22M | $ 5.09M | $ 2.00M | $ -1.67M | |
| $ 32.68M | $ 37.80M | $ 44.69M | $ 52.21M | $ 18.74M | |
| Depreciation and Amortization | $ 1.14M | $ 1.43M | $ 1.35M | $ 2.33M | $ 2.21M |
| $ -9.16M | $ -21.26M | $ -38.28M | $ -46.61M | $ -17.69M | |
| $ -10.30M | $ -22.87M | $ -31.33M | $ -26.39M | $ -20.41M | |
| $ -7.20M | $ -3.68M | $ -1.04M | $ -13.67M | $ 498.00K | |
| $ -17.50M | $ -26.56M | $ -32.38M | $ -40.08M | $ -19.91M | |
| $ -18.03M | $ -26.61M | $ -33.29M | $ -40.44M | $ -19.34M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.02 | $ -0.03 | $ -0.05 | $ -0.17 | $ -0.09 |
| Diluted EPS | $ -0.02 | $ -0.03 | $ -0.05 | $ -0.17 | $ -0.09 |
| Weighted Average Shares Outstanding | 881.34M | 905.20M | 722.54M | 233.19M | 204.41M |
| Weighted Average Shares Outstanding (Diluted) | 881.34M | 905.20M | 722.54M | 233.19M | 204.41M |
Currency in USD
